Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CVKD NASDAQ:INAB NASDAQ:LIAN NASDAQ:SXTP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVKDCadrenal Therapeutics$5.05$5.83$4.21▼$16.25$14.49M1.8166,485 shs47,757 shsINABIN8bio$1.49$1.58$1.17▼$5.61$14.68M0.0863,069 shs130,756 shsLIANLianBio$0.09-19.3%$0.13$0.27▼$4.99$9.74M0.231.04 million shs40,155 shsSXTP60 Degrees Pharmaceuticals$1.39$1.82$1.29▼$14.68$3.67M2.6962,302 shs21,402 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVKDCadrenal Therapeutics0.00%-17.08%-3.26%-8.68%-67.42%INABIN8bio0.00%-5.70%+3.47%-16.29%-61.41%LIANLianBio0.00%-35.64%-25.90%-0.99%-76.28%SXTP60 Degrees Pharmaceuticals0.00%-9.74%-21.91%-60.40%-85.93%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVKDCadrenal Therapeutics$5.05$5.83$4.21▼$16.25$14.49M1.8166,485 shs47,757 shsINABIN8bio$1.49$1.58$1.17▼$5.61$14.68M0.0863,069 shs130,756 shsLIANLianBio$0.09-19.3%$0.13$0.27▼$4.99$9.74M0.231.04 million shs40,155 shsSXTP60 Degrees Pharmaceuticals$1.39$1.82$1.29▼$14.68$3.67M2.6962,302 shs21,402 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVKDCadrenal Therapeutics0.00%-17.08%-3.26%-8.68%-67.42%INABIN8bio0.00%-5.70%+3.47%-16.29%-61.41%LIANLianBio0.00%-35.64%-25.90%-0.99%-76.28%SXTP60 Degrees Pharmaceuticals0.00%-9.74%-21.91%-60.40%-85.93%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCVKDCadrenal Therapeutics 2.00Hold$13.00157.43% UpsideINABIN8bio 2.00Hold$4.00168.46% UpsideLIANLianBio 0.00N/AN/AN/ASXTP60 Degrees Pharmaceuticals 2.25Hold$14.10914.39% UpsideCurrent Analyst Ratings BreakdownLatest SXTP, INAB, CVKD, and LIAN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2026INABIN8bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026CVKDCadrenal Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/9/2026SXTP60 Degrees Pharmaceuticals Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$11.20 ➝ $4.204/7/2026CVKDCadrenal Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$32.00 ➝ $13.003/27/2026SXTP60 Degrees Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/13/2026INABIN8bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 5/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCVKDCadrenal TherapeuticsN/AN/AN/AN/A$1.17 per shareN/AINABIN8bioN/AN/AN/AN/A$2.82 per shareN/ALIANLianBioN/AN/AN/AN/A$2.71 per shareN/ASXTP60 Degrees Pharmaceuticals$1.41M2.60N/AN/A($5.85) per share-0.24Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCVKDCadrenal Therapeutics-$13.24M-$5.63N/AN/AN/AN/A-411.03%-275.61%N/AINABIN8bio-$19.44M-$2.61N/AN/AN/AN/A-96.39%-80.18%8/6/2026 (Estimated)LIANLianBio-$110.29M-$0.81N/AN/AN/AN/A-33.17%-30.19%N/ASXTP60 Degrees Pharmaceuticals-$7.36M-$13.88N/AN/AN/A-574.83%N/A-139.68%N/ALatest SXTP, INAB, CVKD, and LIAN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026SXTP60 Degrees Pharmaceuticals-$0.76-$1.28-$0.52-$1.28$0.44 million$0.16 million5/7/2026Q4 2025CVKDCadrenal Therapeutics-$1.51-$1.04+$0.47-$1.04N/AN/A5/7/2026Q1 2026INABIN8bio-$0.59-$0.26+$0.33-$0.26N/AN/A3/31/2026Q4 2025CVKDCadrenal Therapeutics-$1.17-$1.41-$0.24-$1.41N/AN/A3/12/2026Q4 2025INABIN8bio-$0.18-$0.26-$0.08-$0.26N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCVKDCadrenal TherapeuticsN/AN/AN/AN/AN/AINABIN8bioN/AN/AN/AN/AN/ALIANLianBioN/AN/AN/AN/AN/ASXTP60 Degrees PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCVKDCadrenal TherapeuticsN/A2.682.68INABIN8bioN/A10.5010.50LIANLianBioN/A10.0610.06SXTP60 Degrees PharmaceuticalsN/A2.662.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCVKDCadrenal Therapeutics7.92%INABIN8bio92.05%LIANLianBio74.85%SXTP60 Degrees Pharmaceuticals7.96%Insider OwnershipCompanyInsider OwnershipCVKDCadrenal Therapeutics26.09%INABIN8bio14.50%LIANLianBio7.59%SXTP60 Degrees Pharmaceuticals1.69%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCVKDCadrenal Therapeutics42.87 million2.12 millionNot OptionableINABIN8bio209.85 million8.42 millionNot OptionableLIANLianBio110108.06 million99.86 millionNot OptionableSXTP60 Degrees Pharmaceuticals32.64 million2.59 millionNot OptionableSXTP, INAB, CVKD, and LIAN HeadlinesRecent News About These Companies60 Degrees Pharmaceuticals Announces First Quarter 2026 ResultsMay 15 at 8:42 AM | globenewswire.com60 Degrees Pharmaceuticals (SXTP) Projected to Post Quarterly Earnings on ThursdayMay 14, 2026 | americanbankingnews.com60 Degrees Pharmaceuticals (SXTP) price target decreased by 19.89% to 14.38April 30, 2026 | msn.com60 Degrees Pharma Announces ARAKODA (tafenoquine) for Malaria Prevention is Now Available on Runway Health Travel WebsiteApril 15, 2026 | markets.businessinsider.com60 Degrees Pharmaceuticals Inc. (SXTP) Upgraded to Buy: Here's What You Should KnowApril 3, 2026 | zacks.comInfrastructure Capital and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVApril 2, 2026 | freep.comFInfrastructure Capital and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVApril 2, 2026 | freep.comF60 Degrees Pharmaceuticals Announces 2025 Annual ResultsMarch 31, 2026 | globenewswire.com60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut ExtractMarch 18, 2026 | globenewswire.com60 Degrees Pharmaceuticals Updates Opinion for ATM ProgramMarch 14, 2026 | theglobeandmail.comWhat's going on with 60 Degrees Pharmaceuticals on Friday?March 13, 2026 | msn.com60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical TrialMarch 11, 2026 | globenewswire.com60 Degrees Pharmaceuticals (SXTP) Partners With GoodRx to Expand Access to ARAKODAFebruary 24, 2026 | insidermonkey.com60 Degrees Pharmaceuticals (SXTP) price target increased by 300.00% to 17.95February 4, 2026 | msn.com60 Degrees Pharmaceuticals shares slide after unveiling GoodRx collaborationFebruary 2, 2026 | msn.com60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx PartnershipFebruary 2, 2026 | globenewswire.com60 Degrees Pharmaceuticals Exercises License Option with Florida State University for Large-Scale Purification of Castanospermine for Non-Rx UseJanuary 29, 2026 | finance.yahoo.com60 Degrees Pharmaceuticals shares slide after Nasdaq flags delisting riskJanuary 26, 2026 | msn.com60 Degrees Pharmaceuticals stock tumbles after Nasdaq delisting noticeJanuary 26, 2026 | au.investing.com60 Degrees Pharmaceuticals stock soars on new telehealth partnershipJanuary 22, 2026 | za.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSXTP, INAB, CVKD, and LIAN Company DescriptionsCadrenal Therapeutics NASDAQ:CVKD$5.05 0.00 (0.00%) Closing price 05/15/2026 03:59 PM EasternExtended Trading$5.16 +0.11 (+2.18%) As of 07:49 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.IN8bio NASDAQ:INAB$1.49 0.00 (0.00%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$1.50 +0.01 (+0.47%) As of 08:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company's lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation. The Company is also developing INB-200/400, an autologous genetically modified γδ T cell candidate for newly diagnosed Glioblastoma (GBM). The preclinical pipeline includes a novel γδ T cell engager platform, INB-600, which activates and expands γδ T cells in vivo for deep target cell depletion and is being developed for oncology and autoimmune indications. LianBio NASDAQ:LIAN$0.09 -0.02 (-19.27%) As of 05/15/2026LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.60 Degrees Pharmaceuticals NASDAQ:SXTP$1.39 0.00 (0.00%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$1.39 0.00 (0.00%) As of 08:34 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Peloton Stock Gives Back Gains After Upbeat Earnings Report MarketBeat Week in Review – 05/11 - 05/15 Datavalut Gains Traction: 5 Reasons to Sell Now TMC Stock: Why This Pre-Revenue Miner Is Worth Watching Datadog Soars, Dynatrace Slumps: Gap Widens in AI Agent Stocks Alphabet's Googlebook Brings Gemini AI to PC Hardware As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In Robinhood, SoFi, and Webull Are Telling Very Different Stories Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
